BioSpace News Archive

Ambulatory blood pressure monitors refer to portable devices used for monitoring of a wide range of health conditions associated with hypertension.

Center will contribute to national prioritization of clinical effectiveness through understanding patients as individuals in personalized cancer care.

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, announced the closing of a $100 million Series F financing.

MannKind Corporation and United Therapeutics Corporation reached a major milestone with the announcement that the U.S. Food and Drug Administration accepted for priority review of the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Civica Rx announced that CivicaScript is the name for its operating unit dedicated to lowering the cost of select high-cost generic medicines, and that one of the nation’s largest health insurers and a leading drug manufacturer are joining the initiative.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced financial results for the first quarter ended March 31, 2021.

Elanco Animal Health Incorporated and Kindred Biosciences, Inc. announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

Ault Global Holdings, Inc., a diversified holding company, announced that Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, priced its initial public offering of 2,500,000 shares of common stock at a price to the public of $5.00 per share for gross proceeds of $12.5 million from the offering.

Bright Minds Biosciences, a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company plans to participate in the Raymond James 2021 Human Health Innovation Conference.